Cardiovascular Disease

New hypertension research looks at stress hormones in early disease, the Quadpill as first Rx, tight BP control for older adults--for a start. We recap 8 new studies.

CCTA identified atherosclerosis in >40% of middle-aged adults without known coronary heart disease, report Swedish investigators; significant stenosis was found in another 5.2%.

Dapagliflozin adds substantial improvements in symptoms, exercise function to demonstrated disease-modifying properties for patients with HFpEF.

Identifying white coat and masked hypertension is essential for prevention of CV morbidity and mortality. Review the ACC/AHA recommendations on how to detect and manage.

Each doubling of levels of 4 stress hormones was associated with a 21-31% increase in risk of developing hypertension over a median 6.5-year follow-up.

New research suggests frequent cannabis use can raise the risk of myocardial infarction in adults younger than 45 years.

Patients with HIV had a 14% higher risk of sudden cardiac death than those without HIV, according to a large analysis of US veterans.

ESC Congress 2021: Results from the largest trial of its kind suggest that flu vaccination should be part of in-hospital treatment after myocardial infarction.

Aggressive control of systolic BP in adults aged 60 to 80 years significantly reduced CV risk, adding to evidence from the pivotal SPRINT trial in support of tight BP control.

Substituting regular salt with low-sodium alternative was found to reduce the risk of stroke, major cardiovascular events, and death in a new study presented at ESC Congress 2021.

Finerenone, in patients with mild-to-moderate renal disease and T2D, reduced CV event risk by 13% and risk for a composite renal event by 23%, study authors reported at ESC 2021.

In a pooled analysis of 2 key clinical trials, empagliflozin was beneficial in patients with heart failure with a reduced and preserved ejection fraction.

Empagliflozin in patients with HFpEF reduced by 21% the risk of cardiovascular death or heart failure hospitalization across all prespecified subgroups, including those with/without diabetes.

The ESC Congress 2021, Aug 27-30, 2021, is here. For primary care, we highlight the "Hot Lines" clinical trial presentations where new data from novel trials will premier.

Consuming saturated fat from meat may be associated with a higher risk of CVD than other food sources, according to a new study presented at ESC Congress 2021.

Periodontitis was associated with an increased risk for CVD, particularly among patients with past myocardial infarction, in a new study being presented at ESC Congress 2021.

New findings being presented at ESC Congress 2021 highlight the need for smoking cessation services tailored to the specific needs of women.

With the post-LER PAD indication, rivaroxaban becomes the only anticoagulant in 2 decades to demonstrate safety and efficacy in the high-risk population.

Younger adults with myocardial infarction are more likely to be smokers, obese, and have hypertension than their peers, suggests a new study being presented at the ESC Congress 2021.

COVID-19 patients after just 5 days or less in the hospital report new or worsened symptoms, impaired daily function, and significant financial loss.

Delaying or forfeiting care for HF significantly increased future health care costs, a finding at odds, say study authors, with the inability to afford regular treatment.

A recent meta-analysis found that consuming up to 105 g of alcohol a week was associated with lower risks of cardiovascular events and mortality among adults with CVD.

Take this quick quiz to test your knowledge of key findings in landmark studies on the cardioprotective effects of SGLT2i and GLP-1 RAs.

Patients with overweight and obesity rarely received guidance on weight management after hospitalization for a coronary event, authors report.

Eating a more plant-centered diet was associated with lower risk for CVD among both young adults and postmenopausal women, according to two new studies.

As FHS continues, advanced technology leads to discovery of genetic CVD risk; imaging studies refine risk assessment; gamification enters FHS research; and a 2019 grant ensures the future.

These concise summaries highlight the latest findings on the cardioprotective effects of SGLT2 inhibitors and GLP-1 RA in patients with diabetes.

Findings from the Framingham Heart Study since its 1948 beginning have led to identification of and treatment for dozens of risk factors for cardiovascular disease. Which ones?

Results of a new systematic review and meta-analysis by researchers at Penn State College of Medicine underscore needs for patient education and additional research on prevention.

Nathan D Wong, PhD, MPH, renowned in the field of preventive cardiology, reviewed for Patient Care the history of the field and his own pivotal contributions and also paid tribute to his lifetime mentors.